DE60209704D1 - Neue kristallforme von azithromycin - Google Patents

Neue kristallforme von azithromycin

Info

Publication number
DE60209704D1
DE60209704D1 DE60209704T DE60209704T DE60209704D1 DE 60209704 D1 DE60209704 D1 DE 60209704D1 DE 60209704 T DE60209704 T DE 60209704T DE 60209704 T DE60209704 T DE 60209704T DE 60209704 D1 DE60209704 D1 DE 60209704D1
Authority
DE
Germany
Prior art keywords
azithromycin
crystal form
new crystal
new
crystal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE60209704T
Other languages
English (en)
Other versions
DE60209704T2 (de
Inventor
Jane Li
Vincent Trask
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27404135&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60209704(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Application granted granted Critical
Publication of DE60209704D1 publication Critical patent/DE60209704D1/de
Publication of DE60209704T2 publication Critical patent/DE60209704T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
DE60209704T 2001-05-22 2002-05-01 Neue kristallforme von azithromycin Revoked DE60209704T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US29256501P 2001-05-22 2001-05-22
US292565P 2001-05-22
US29774101P 2001-06-12 2001-06-12
US297741P 2001-06-12
US34304101P 2001-12-21 2001-12-21
US343041P 2001-12-21
PCT/IB2002/001570 WO2002094843A1 (en) 2001-05-22 2002-05-01 Crystal forms of azithromycin

Publications (2)

Publication Number Publication Date
DE60209704D1 true DE60209704D1 (de) 2006-05-04
DE60209704T2 DE60209704T2 (de) 2006-11-16

Family

ID=27404135

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60228345T Expired - Lifetime DE60228345D1 (de) 2001-05-22 2002-05-01 Neue Kristallforme von Azithromycin
DE60209704T Revoked DE60209704T2 (de) 2001-05-22 2002-05-01 Neue kristallforme von azithromycin

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE60228345T Expired - Lifetime DE60228345D1 (de) 2001-05-22 2002-05-01 Neue Kristallforme von Azithromycin

Country Status (35)

Country Link
US (10) US6977243B2 (de)
EP (1) EP1390377B1 (de)
JP (3) JP2004530703A (de)
KR (1) KR100574153B1 (de)
AP (1) AP2003002906A0 (de)
AR (1) AR036022A1 (de)
AT (2) ATE319730T1 (de)
AU (1) AU2002256846B2 (de)
BG (1) BG108370A (de)
BR (1) BR0209918A (de)
CA (1) CA2391659C (de)
CR (1) CR7159A (de)
CZ (1) CZ20033154A3 (de)
DE (2) DE60228345D1 (de)
DK (1) DK1390377T3 (de)
EA (2) EA007618B1 (de)
EE (1) EE200300575A (de)
ES (2) ES2258142T3 (de)
GE (1) GEP20084399B (de)
HU (1) HUP0400446A2 (de)
IL (1) IL158591A0 (de)
IS (1) IS7007A (de)
MA (1) MA27023A1 (de)
MX (1) MXPA03010028A (de)
MY (1) MY129319A (de)
NO (2) NO321894B1 (de)
NZ (2) NZ539801A (de)
PA (1) PA8545701A1 (de)
PE (1) PE20021064A1 (de)
PL (1) PL367091A1 (de)
PT (1) PT1390377E (de)
SK (1) SK14402003A3 (de)
TN (1) TNSN03121A1 (de)
WO (1) WO2002094843A1 (de)
YU (1) YU91603A (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20020231A2 (en) 2002-03-18 2003-12-31 Pliva D D ISOSTRUCTURAL PSEUDOPOLYMORPHS OF 9-DEOXO-9a-AZA-9a-METHYL-9a-HOMOERYTHROMYCIN A
AU768219B2 (en) * 1998-11-30 2003-12-04 Teva Pharmaceutical Industries Ltd. Ethanolate of azithromycin, process for manufacture, and pharmaceutical compositions thereof
WO2002015842A2 (en) * 2000-08-23 2002-02-28 Wockhardt Limited Process for preparation of anhydrous azithromycin
KR100431431B1 (ko) * 2001-04-25 2004-05-14 한미약품 주식회사 아지트로마이신 수화물의 1,2-프로필렌글리콜 내포화합물,그의 제조방법 및 그의 약학적 조성물
ATE319730T1 (de) * 2001-05-22 2006-03-15 Pfizer Prod Inc Neue kristallforme von azithromycin
ITMI20011762A1 (it) 2001-08-10 2003-02-10 Cosmo Spa Esteri di 17alfa,21-diidrossipregnene, loro uso come agenti anti-androgenetici e procedimenti per la loro preparazione
MXPA04003027A (es) * 2001-12-21 2004-07-05 Pfizer Prod Inc Metodos para granulacion humeda de azitromicina.
IL161996A0 (en) * 2001-12-21 2005-11-20 Pfizer Prod Inc Directly compressible formulations of azithromycin
JP2005526020A (ja) 2002-02-01 2005-09-02 ファイザー・プロダクツ・インク アジスロマイシンの乾式造粒配合物
HRP20020614A2 (en) * 2002-07-22 2004-06-30 PLIVA-ISTRAŽIVAČKI INSTITUT d.o.o. Rhombic pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin a
CA2422972A1 (en) * 2003-03-21 2004-09-21 Apotex Inc. Isopropanolate of azithromycin and method of manufacturing
US20050013835A1 (en) * 2003-07-15 2005-01-20 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
EP1878432A1 (de) * 2003-07-24 2008-01-16 Pliva - Research and Development Ltd. Schnellösliches Azithromycin in Einzeldosisform
ATE421882T1 (de) 2003-07-24 2009-02-15 Pliva Hrvatska D O O Schnellösliches azithromycin in einzeldosisform
RU2434870C2 (ru) * 2003-11-17 2011-11-27 Мерк Эпрова Аг Кристаллические формы дигидрохлорида (6r)-l-эритро-тетрагидробиоптерина
US7943585B2 (en) 2003-12-22 2011-05-17 Sandoz, Inc. Extended release antibiotic composition
US20060116336A1 (en) * 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
US7468428B2 (en) * 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
US20050250714A1 (en) * 2004-05-06 2005-11-10 Lin Kangwen L Crystalline forms of 9-(S)-erythromycylamine
EP1776365B1 (de) * 2004-06-02 2011-08-03 Sandoz Ag Meropenem-zwischenprodukt in kristalliner form
US7683162B2 (en) 2004-08-30 2010-03-23 Taro Pharmaceutical Industries Limited Process of preparing a crystalline azithromycin monohydrate
US8495244B2 (en) * 2005-06-29 2013-07-23 Jumpstart Wireless Corporation System and method for dynamic automatic communication path selection, distributed device synchronization and task delegation
US7750153B2 (en) * 2005-07-05 2010-07-06 Hetero Drugs Limited Process for the preparation of didanosine using novel intermediates
WO2007007148A1 (en) * 2005-07-14 2007-01-18 Pfizer Products Inc. Process for forming amorphous azithromycin particles
CA2622670A1 (en) * 2005-09-21 2007-04-12 Nycomed Gmbh Sulphonylpyrrole hydrochloride salts as histone deacetylases inhibitors
AU2006309077A1 (en) * 2005-10-31 2007-05-10 Janssen Pharmaceutica N.V. Novel processes for the preparation of piperazinyl and diazapanyl benzamide derivatives
US8558765B2 (en) * 2005-11-07 2013-10-15 Global Oled Technology Llc Method and apparatus for uniformity and brightness correction in an electroluminescent display
WO2007144006A1 (en) * 2006-06-16 2007-12-21 H. Lundbeck A/S Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
US7919598B2 (en) * 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
KR20090084891A (ko) * 2006-10-27 2009-08-05 시그날 파마소티칼 엘엘씨 4-[9-(테트라하이드로-퓨란-3-일)-8-(2,4,6-트리플루오로-페닐아미노)-9ｈ-퓨린-2-일아미노]-사이클로헥산-1-올을 포함하는 고체 형태들, 이들의 조성물들 및 이들의 용도
CA2570949A1 (en) * 2006-12-12 2008-06-12 Apotex Pharmachem Inc. Ibandronate sodium propylene glycol solvate and processes for the preparation thereof
US7834195B2 (en) 2007-01-24 2010-11-16 Apotex Pharmachem Inc. Atorvastatin calcium propylene glycol solvates
ITMI20071616A1 (it) * 2007-08-03 2009-02-04 Cosmo Spa Processo enzimatico per l'ottenimento di 17-alfa monoesteri del cortexolone e/o suoi 9,11-deidroderivati.
US7919676B2 (en) 2007-08-03 2011-04-05 Pioneer Hi-Bred International, Inc. Msca1 nucleotide sequences impacting plant male fertility and method of using same
EP2085397A1 (de) * 2008-01-21 2009-08-05 Esteve Quimica, S.A. Kristalline Form von Abacavir
US7935817B2 (en) * 2008-03-31 2011-05-03 Apotex Pharmachem Inc. Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof
AR071318A1 (es) * 2008-04-15 2010-06-09 Basilea Pharmaceutica Ag Benzhidril ester del acido (6r,7r)-7-{2-(5-amino-[1,2,4]tiadiazol-3-il)-2-[(z)-tritiloxiimino]-acetilamino}-3-[(r)-1'-terc-butoxicarbonil-2-oxo-[1,3']bipirrolidinil-(3e)-ilidenometil]-8-oxo-5-tia-1-aza-biciclo[4.2.0]oct-2-eno-2-carboxilico cristalino; su elaboracion y uso
US8097719B2 (en) * 2008-07-15 2012-01-17 Genesen Labs Meropenem intermediate in novel crystalline form and a method of manufacture of meropenem
US8216363B2 (en) * 2008-10-27 2012-07-10 Illinois Institute Of Technology Continuous antisolvent crystallization process and system using plug flow reactors
US20100158821A1 (en) * 2008-12-22 2010-06-24 Eastman Chemical Company Antimicrobial agents, compositions and products containing the same, and methods of using the compositions and products
US20120058936A1 (en) 2009-03-13 2012-03-08 Assistance Publique - Hopitaux De Paris Compositions and methods for elimination of gram negative bacteria
US8106111B2 (en) 2009-05-15 2012-01-31 Eastman Chemical Company Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions
EP2544679B1 (de) 2010-03-12 2019-05-15 Omeros Corporation Pde10-hemmer sowie entsprechende zusammensetzungen und verfahren
SG188361A1 (en) * 2010-09-01 2013-04-30 Arena Pharm Inc Non-hygroscopic salts of 5-ht2c agonists
CN103930419B (zh) * 2011-09-30 2016-06-01 广东东阳光药业有限公司 阿齐沙坦的晶型及其制备方法
WO2013088274A1 (en) 2011-12-14 2013-06-20 Wockhardt Limited Anhydrous amorphous azithromycin composition free of azithromycin dihydrate
NZ716494A (en) 2014-04-28 2017-07-28 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
NZ716462A (en) * 2014-04-28 2017-11-24 Omeros Corp Optically active pde10 inhibitor
RU2017134509A (ru) 2015-04-24 2019-04-04 Омерос Корпорейшн Ингибиторы pde10 и соответствующие композиции и способы
EP3108879A1 (de) 2015-06-25 2016-12-28 Cassiopea S.p.A. Hochkonzentrierte formulierung
US9920045B2 (en) 2015-11-04 2018-03-20 Omeros Corporation Solid state forms of a PDE10 inhibitor
CN111303230B (zh) * 2020-03-09 2021-07-13 中国食品药品检定研究院 一种黄体酮共晶物及其制备方法和用途

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU43116B (en) 1979-04-02 1989-04-30 Pliva Pharm & Chem Works Process for preparing 11-aza-4-o-cladinosyl-6-o-desosaminyl-15-ethyl-7,13,14-trihydroxy-3,5,7,9,12,14-hexamethyl-oxacyclopentadecane-2-one(11-aza-10-deox
SI8110592A8 (en) 1981-03-06 1996-06-30 Pliva Pharm & Chem Works Process for preparing of n-methyl-11-aza-10-deoxo-10-dihydroerythromycine a and derivatives thereof
US4474768A (en) 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
US4465674A (en) 1983-09-06 1984-08-14 Pfizer Inc. Azahomoerythromycin D derivative and intermediates therefor
MX12213A (es) 1987-07-09 1993-05-01 Pfizer Metodo de preparacion de dihidrato de azitromicina cristalino
WO1989002271A1 (en) 1987-09-10 1989-03-23 Pfizer Azithromycin and derivatives as antiprotozoal agents
US4983531A (en) * 1990-02-12 1991-01-08 Motorola, Inc. Method of fabricating a single polysilicon bipolar transistor which is compatible with a method of fabricating CMOS transistors
CN1093370A (zh) * 1993-12-10 1994-10-12 北京市集才药物研究所 一种新的阿齐红霉素结晶及其制备方法
CN1034734C (zh) 1993-12-10 1997-04-30 北京市集才药物研究所 一种新的阿齐红霉素结晶及其制备方法
US5605889A (en) * 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
DE69730138T2 (de) * 1996-07-29 2005-03-03 Abbott Laboratories, Abbott Park Herstellung von kristallinen form ii von clarithromycin
CN1161971A (zh) 1997-01-03 1997-10-15 石家庄制药集团有限公司 一种阿齐霉素结晶及其制备方法
PT102130A (pt) 1998-03-13 1999-09-30 Hovione Sociedade Quimica S A Processo de preparacao de dihidrato de azitromicina
TW546302B (en) 1998-05-08 2003-08-11 Biochemie Sa Improvements in macrolide production
CA2245398C (en) * 1998-08-21 2002-01-29 Apotex Inc. Azithromycin monohydrate isopropanol clathrate and methods for the manufacture thereof
KR100377159B1 (ko) * 1998-09-09 2003-08-19 한미약품공업 주식회사 잔류 용매가 없는 클라리스로마이신의 결정형 2의 제조 방법
AU768219B2 (en) * 1998-11-30 2003-12-04 Teva Pharmaceutical Industries Ltd. Ethanolate of azithromycin, process for manufacture, and pharmaceutical compositions thereof
DE60029589T2 (de) * 1999-06-29 2007-07-19 Sandoz Ag Verfahren zur herstellung von azithromycin
ES2177373B1 (es) * 1999-11-26 2003-11-01 Astur Pharma Sa Preparacion de azitromicina en su forma no cristalina
CA2396426A1 (en) 2000-01-04 2001-07-12 Teva Pharmaceutical Industries Ltd. Preparation method of azithromycin dihydrate
ES2162764B1 (es) 2000-05-17 2003-04-01 Ercros Ind Sa Forma polimorfica del dihidrato de azitromicina, y su procedimiento deobtencion.
WO2002007736A1 (en) 2000-07-24 2002-01-31 Cadila Pharmaceuticals Limited The process for manufacturing of clear liquid pharmaceutical composition of azithromycin
WO2002010144A1 (es) 2000-07-25 2002-02-07 Laboratorio Silanes, S.A. De C.V. PROCESO PARA LA PREPARACION EN UN SOLO PASO DE 7,16-DIOXA-2-AZA-10-O-CLADINOSIL-12-O-DESOSAMINIL-4,5-DIHIDROXI-6-ETIL-3,5,9,11,13,15-HEXAMETILBICICLO[11.2.1]HEXADECA-1(2)-EN-8-ONA Y OBTENCION DE UNA FORMA NUEVA DE 9-DESOXO-9a-AZA-9a-METIL-9a-HOMOERITROMICINA A
ITBO20000471A1 (it) 2000-07-31 2002-01-31 Vieri Ridolfi Dispositivo di supporto per prodotti da fumo particolarmente sigarette .
ES2172417B1 (es) 2000-07-31 2003-09-16 Sint Quimica Sa Nueva forma mejorada de azitromicina monohidrato de menor higroscopicidad, procedimiento de preparacion y composiciones farmaceuticas que la comprenden.
AU2001214115A1 (en) 2000-08-01 2002-02-13 Habil F. Khorakiwala Process for the preparation of anhydrous azithromycin
WO2002015842A2 (en) 2000-08-23 2002-02-28 Wockhardt Limited Process for preparation of anhydrous azithromycin
CA2429639C (en) 2000-11-27 2009-07-14 Biochemie S.A. Stable azithromycin monohydrate
IN190080B (de) 2001-01-29 2003-06-07 Alembic Ltd
KR100431431B1 (ko) 2001-04-25 2004-05-14 한미약품 주식회사 아지트로마이신 수화물의 1,2-프로필렌글리콜 내포화합물,그의 제조방법 및 그의 약학적 조성물
ATE319730T1 (de) * 2001-05-22 2006-03-15 Pfizer Prod Inc Neue kristallforme von azithromycin
US6861413B2 (en) * 2001-05-22 2005-03-01 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
IL161398A0 (en) 2001-10-18 2004-09-27 Teva Pharma Stabilized azithromycin compositions

Also Published As

Publication number Publication date
EA007618B1 (ru) 2006-12-29
JP4584162B2 (ja) 2010-11-17
EA200500630A1 (ru) 2006-02-24
US6977243B2 (en) 2005-12-20
AP2003002906A0 (en) 2003-12-31
MY129319A (en) 2007-03-30
CA2391659A1 (en) 2002-11-22
US20040138149A1 (en) 2004-07-15
DK1390377T3 (da) 2006-06-19
US20050245469A1 (en) 2005-11-03
NO20035177D0 (no) 2003-11-21
ES2310886T3 (es) 2009-01-16
JP2007161726A (ja) 2007-06-28
US7307156B2 (en) 2007-12-11
NO321894B1 (no) 2006-07-17
IS7007A (is) 2003-10-30
EP1390377A1 (de) 2004-02-25
AR036022A1 (es) 2004-08-04
TNSN03121A1 (en) 2005-12-23
US20040043945A1 (en) 2004-03-04
US7105179B2 (en) 2006-09-12
YU91603A (sh) 2006-08-17
EA009611B1 (ru) 2008-02-28
ES2258142T3 (es) 2006-08-16
NZ539801A (en) 2006-10-27
BR0209918A (pt) 2004-03-30
JP2006152002A (ja) 2006-06-15
MA27023A1 (fr) 2004-12-20
US7309782B2 (en) 2007-12-18
US20050256063A1 (en) 2005-11-17
US7282486B2 (en) 2007-10-16
AU2002256846B2 (en) 2007-04-05
US20050090459A1 (en) 2005-04-28
WO2002094843A1 (en) 2002-11-28
IL158591A0 (en) 2004-05-12
EE200300575A (et) 2004-04-15
DE60209704T2 (de) 2006-11-16
ATE319730T1 (de) 2006-03-15
HUP0400446A2 (hu) 2004-09-28
US20040043944A1 (en) 2004-03-04
MXPA03010028A (es) 2004-02-12
NO20061049L (no) 2003-05-12
PT1390377E (pt) 2006-06-30
CZ20033154A3 (en) 2004-04-14
PA8545701A1 (es) 2003-09-05
US20050192234A1 (en) 2005-09-01
US20050256062A1 (en) 2005-11-17
GEP20084399B (en) 2008-06-10
US7053192B2 (en) 2006-05-30
BG108370A (bg) 2004-11-30
DE60228345D1 (de) 2008-09-25
CA2391659C (en) 2006-05-30
SK14402003A3 (sk) 2004-06-08
ATE404575T1 (de) 2008-08-15
KR20040014525A (ko) 2004-02-14
US7081525B2 (en) 2006-07-25
CR7159A (es) 2004-02-23
NZ529118A (en) 2005-10-28
US20030162730A1 (en) 2003-08-28
JP2004530703A (ja) 2004-10-07
US20040082527A1 (en) 2004-04-29
PL367091A1 (en) 2005-02-21
EP1390377B1 (de) 2006-03-08
KR100574153B1 (ko) 2006-04-25
PE20021064A1 (es) 2002-11-21
EA200301115A1 (ru) 2004-04-29

Similar Documents

Publication Publication Date Title
DE60209704D1 (de) Neue kristallforme von azithromycin
DE60239146D1 (de) Neue kristalline verbindung
DE60236581D1 (de) Ng von mosaikeffekten
DE60211601D1 (de) Bereitstellung von positionsabhängigen Inhalten
DE02784674T1 (de) Quantifizierung von polypeptiden
DK1440083T3 (da) Molekyler
DE60219451D1 (de) Flüssigkristallanzeige
DE60234074D1 (de) Flüssigkristallanzeige
DE60227828D1 (de) E von schmelzkleber
DE60111435D1 (de) Flüssigkeitskühlung von Glasformen
DK1451433T3 (da) Glassammensætning
DE60031450D1 (de) Polymorph v von torasemid
DE60007360T2 (de) Amorphe modifikation von torasemid
ATE293113T1 (de) Neue polymorphe formen von olanzapin
DE50109358D1 (de) Flüssigkristall-Anzeige
DE50203067D1 (de) Quarzoszillatorschaltung
AT503224A3 (de) Holzbautafel
DE60208824D1 (de) Verbesserungen von elektromechanischen aktuatoren
DE60217710D1 (de) Neue formulierung
ATA5002002A (de) Vibrator
DE60211186D1 (de) Neue verwendung substituierter aminomethylchromane
DE60206043D1 (de) Neue indolderivate
DE60223782D1 (de) Kombination von Frontplatten
ATE348606T1 (de) Neue verwendung von pipatalin
DE50203046D1 (de) Verwendung von Esterquats

Legal Events

Date Code Title Description
8363 Opposition against the patent
8331 Complete revocation